ARMP armatapharma.com: Total Company Value-to-Revenue Ratio

armatapharma.com (ARMP) - corporate logo

Armata Pharmaceuticals (ARMP) is developing innovative treatments against superbugs based on unique patents, while strict financial control by the Innoviva fund minimizes expenditure risks. The enterprise value-to-annual revenue multiple visualizes this trend, where the 45574.83 mark reflects the latest data. Stringent FDA requirements and testing costs limit competitor access, maintaining the asset's speculative nature until trials are completed.

ARMP Armata Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

Armata Pharmaceuticals Inc - analytical breakdowns and key metrics (ARMP)

- price and consensus price forecast:
Fundamental valuation:Armata Pharmaceuticals (ARMP)
Manufactured product of Armata Pharmaceuticals, Inc.

EV/Sales (co) measures the total enterprise value, including debt, relative to annual revenue to determine the market revaluation of assets. Investors utilize this multiple to analyze revenue generation efficiency relative to capitalization. The current enterprise value-to-sales level reflects the speculative nature of the Armata Pharmaceuticals (ARMP) valuation. High development costs for bacteriophages make this metric sensitive to Phase 2 expectations, and a compression of this indicator could signal a reassessment of R&D risks.

Competitor analysis for Armata Pharmaceuticals